Our physician scientists work with a talented group of researchers to investigate the causes of immune system disorders. We collaborate with pharmaceutical companies in the Boston area to develop new treatments for lupus and other autoimmune diseases.

Our patients are vital partners in this research. We are currently enrolling patients with all forms of lupus, patients with autoimmune diseases other than lupus, and patients with chronic kidney disease in an Autoimmune Disease Registry and Repository. The goal of the registry and repository is to use patient samples collected for research purposes to advance our understanding of how the immune system attacks healthy cells and causes organ injury and to identify new targets for therapy.

We are also enrolling patients in research studies that involve a single blood donation to compare immune cell function between diseased individuals and healthy volunteers and to investigate how variations in genes (inherited from your parents) may contribute to the development of lupus.

If you are interested in participating in one of our research studies, please contact Carlos Sian at 617.638.5965.

To learn more about lupus research at Boston Medical Center, please visit our team members’ profiles.

Clinical Trials

Many of lupus patients, despite receiving the standard-of-care treatment for lupus or lupus nephritis, still do not achieve a complete remission. Some patients cannot tolerate the standard-of-care treatments because they develop significant side effects.

We offer patients the opportunity to participate in clinical trials and receive investigational treatments for lupus. Investigational treatments are medications that are not currently approved by the Food and Drug Administration to treat lupus. To learn more about what a clinical trial is, visit clinicaltrials.gov and select “About Clinical Studies.”

We are currently enrolling patients in the following clinical trials:

I. Sponsor: Genentech

Study Drug: GDC-0853, a Btk inhibitor

Patient population: Systemic lupus erythematosus (SLE)

Title of study: A Phase II, randomized, double-blind, placebo-controlled study of the safety and efficacy of GDC-0853 in patients with moderate to severe active systemic lupus erythematosus

For more information about the outcome measures of the study and eligibility criteria, visit clinicaltrials.gov and type in the identifier NCT02908100

If you are interested in participating in one of our research studies, please contact Carlos Sian at 617.638.5965.